408 related articles for article (PubMed ID: 28836191)
1. Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
Rosenbloom J; Macarak E; Piera-Velazquez S; Jimenez SA
Methods Mol Biol; 2017; 1627():1-23. PubMed ID: 28836191
[TBL] [Abstract][Full Text] [Related]
2. Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic disease.
Sampson N; Berger P; Zenzmaier C
Biomed Res Int; 2014; 2014():131737. PubMed ID: 24701562
[TBL] [Abstract][Full Text] [Related]
3. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.
Wei J; Bhattacharyya S; Tourtellotte WG; Varga J
Autoimmun Rev; 2011 Mar; 10(5):267-75. PubMed ID: 20863909
[TBL] [Abstract][Full Text] [Related]
4. Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases.
Hinz B; Lagares D
Nat Rev Rheumatol; 2020 Jan; 16(1):11-31. PubMed ID: 31792399
[TBL] [Abstract][Full Text] [Related]
5. Excessive exosome release is the pathogenic pathway linking a lysosomal deficiency to generalized fibrosis.
van de Vlekkert D; Demmers J; Nguyen XX; Campos Y; Machado E; Annunziata I; Hu H; Gomero E; Qiu X; Bongiovanni A; Feghali-Bostwick CA; d'Azzo A
Sci Adv; 2019 Jul; 5(7):eaav3270. PubMed ID: 31328155
[TBL] [Abstract][Full Text] [Related]
6. Cellular Transdifferentiation: A Crucial Mechanism of Fibrosis in Systemic Sclerosis.
Jimenez SA; Piera-Velazquez S
Curr Rheumatol Rev; 2024; 20(4):388-404. PubMed ID: 37921216
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of fibrosis: therapeutic translation for fibrotic disease.
Wynn TA; Ramalingam TR
Nat Med; 2012 Jul; 18(7):1028-40. PubMed ID: 22772564
[TBL] [Abstract][Full Text] [Related]
8. Promising small molecule anti-fibrotic agents: Newly developed or repositioned drugs targeting myofibroblast transdifferentiation.
Ishikane S; Arioka M; Takahashi-Yanaga F
Biochem Pharmacol; 2023 Aug; 214():115663. PubMed ID: 37336252
[TBL] [Abstract][Full Text] [Related]
9. New Insights into the Role of KLF10 in Tissue Fibrosis.
Yaseen U; Hwang S; Park S; Kim SB; Lee HJ; Cha JY
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279278
[TBL] [Abstract][Full Text] [Related]
10. Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.
Taherian M; Bayati P; Mojtabavi N
Stem Cell Res Ther; 2024 Jun; 15(1):170. PubMed ID: 38886859
[TBL] [Abstract][Full Text] [Related]
11. Molecular determinants of mesenchymal cell activation in fibroproliferative diseases.
Penke LR; Peters-Golden M
Cell Mol Life Sci; 2019 Nov; 76(21):4179-4201. PubMed ID: 31563998
[TBL] [Abstract][Full Text] [Related]
12. The contribution of mesenchymal transitions to the pathogenesis of systemic sclerosis.
Rosa I; Romano E; Fioretto BS; Manetti M
Eur J Rheumatol; 2020 Oct; 7(Suppl 3):S157-S164. PubMed ID: 31922472
[TBL] [Abstract][Full Text] [Related]
13. The pathogenesis of cardiac fibrosis.
Kong P; Christia P; Frangogiannis NG
Cell Mol Life Sci; 2014 Feb; 71(4):549-74. PubMed ID: 23649149
[TBL] [Abstract][Full Text] [Related]
14. S100A4 a classical DAMP as a therapeutic target in fibrosis.
O'Reilly S
Matrix Biol; 2024 Mar; 127():1-7. PubMed ID: 38219976
[TBL] [Abstract][Full Text] [Related]
15. Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis.
Vistnes M
Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543053
[TBL] [Abstract][Full Text] [Related]
16. Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit.
Massoud G; Parish M; Hazimeh D; Moukarzel P; Singh B; Cayton Vaught KC; Segars J; Islam MS
Int Immunopharmacol; 2024 Jun; 137():112423. PubMed ID: 38861914
[TBL] [Abstract][Full Text] [Related]
17. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases.
Wermuth PJ; Jimenez SA
Clin Transl Med; 2015; 4():2. PubMed ID: 25852818
[TBL] [Abstract][Full Text] [Related]
18. Integrin-mediated regulation of TGFβ in fibrosis.
Henderson NC; Sheppard D
Biochim Biophys Acta; 2013 Jul; 1832(7):891-6. PubMed ID: 23046811
[TBL] [Abstract][Full Text] [Related]
19. Fibrosis-on-Chip: A Guide to Recapitulate the Essential Features of Fibrotic Disease.
Streutker EM; Devamoglu U; Vonk MC; Verdurmen WPR; Le Gac S
Adv Healthc Mater; 2024 Mar; ():e2303991. PubMed ID: 38536053
[TBL] [Abstract][Full Text] [Related]
20. Senescence and tissue fibrosis: opportunities for therapeutic targeting.
O'Reilly S; Tsou PS; Varga J
Trends Mol Med; 2024 Jun; ():. PubMed ID: 38890028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
